Directed the strategic realignment of METiS’ LNP technology portfolio, driving business continuity, risk management, and maximizing the company’s potential in a highly competitive market.Identified growth opportunities for partnerships, focusing on the evolving needs of the LNP market to identify where innovation could advance musculoskeletal, neurological and pulmonary disease treatment. Spearheaded METiS' strategic initiatives for market entry into the US and EU markets, leading crossfunctional teams to secure over $250K in upfront payments and up to $2B in potential value through MTAs and Option Agreements.Led a team that managed partnership efforts across the US and EU through skilled communication, collaboration, and strategic planning, ensuring alignment with organizational goals and continuous improvement initiatives.Enhanced METiS' profile by presenting strategic plans and scientific data at key scientific and business conferences, generating a strong influence on executive leadership and company-wide decision-making.

Executed over 35 projects related to business opportunities, including asset acquisition due diligence and corporate strategy development.Specialized in the gene therapy space, applying life sciences expertise to develop innovative solutions for complex diseases.Led organizational change management initiatives, focusing on the strategic goals and performance culture of client companies.Facilitated team development and collaboration, ensuring alignment with strategic plans and continuous improvement objectives.Provided guidance and mentorship to junior consultants, fostering a culture of analytical skills and critical thinking.

Innovated in protein engineering and nanoparticle technology, leading to advancements in non-viral genetic engineering methods.Pioneered collaboration with international research teams, enhancing leadership and project management capabilities.Managed a multidisciplinary team, overseeing project planning, execution, and risk management for successful outcomes. Presented research findings to scientific and commercial stakeholders, resulting in four first author publications

Investigated the interactions between nanomaterials and biological microenvironments, contributing to regulatory science applications.Employed advanced analytical skills and MATLAB modeling to analyze nanomaterial behavior in vitro. Gained exposure to European Union consortium projects, developing a deep understanding of international regulatory frameworks.

Worked at the Fei Wen Research lab, where I conducted research in protein engineering for the breakdown of cellulose molecules.

Worked at the Brian Pfleger research lab where I worked on the building of bioreactors and genetic modification of cyanobacteria for the aim of producing bio-fuels.